Global Wellness Times
SEE OTHER BRANDS

Global take on healthcare and wellness news

Global Wellness Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Wellness Times.

Press releases published on May 13, 2025

Caliber Hospitality Development Launches to Pursue Opportunistic and Distressed Hotel Investments

Caliber Hospitality Development Launches to Pursue Opportunistic and Distressed Hotel Investments

SCOTTSDALE, Ariz., May 13, 2025 (GLOBE NEWSWIRE) -- Caliber (NASDAQ: CWD), a real estate investor, developer, and manager, today announced the launch of Caliber Hospitality Development, LLC (“CHD”), a joint venture between Caliber and GIA Hospitality, LLC …

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

- ATTRibute-CM, BridgeBio’s Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients (59.1% risk reduction), establishing the mechanistic …

XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements

XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements

Pipeline advancements: The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen’s tovorafenib was accepted for review by the European Marketing Authority (EMA) and Takeda initiated its Phase 3 trial exploring mezagitamab for …

Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates …

BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights

BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights

Achieved record quarterly sales of $11.5 million in Q1 2025, an increase of 27% compared to Q1 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.3 million, increasing by 519% and 81%, respectively, compared to Q1 of 2024 Shipped a …

Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative …

Knight to Present at the 2025 RBC Capital Markets Global Healthcare Conference in New York City

Knight to Present at the 2025 RBC Capital Markets Global Healthcare Conference in New York City

MONTREAL, May 13, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:  GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a …

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

YAVNE, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post hoc analysis in Wounds. The analysis is …

Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference

Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, …

NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%

NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%

Filed 510(k)Submission with FDA for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule Company Fully Funded Through at Least Fiscal Year 2026 Following Oversubscribed $8.2 Million Capital Raise EDEN PRAIRIE, Minn., May 13, 2025 …

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

- Commenced market launch and first commercial sales of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Total revenues of $517,000 for quarter from sales and collaborative research agreement – - …

Knight présentera à la conférence sur la santé internationale de 2025 de RBC Marchés des Capitaux à New York

Knight présentera à la conférence sur la santé internationale de 2025 de RBC Marchés des Capitaux à New York

MONTRÉAL, 13 mai 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (ex-ÉU), a annoncé aujourd'hui que Samira Sakhia, présidente et chef de la direction, participera à une …

Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program

Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program

Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025 SEATTLE and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. …

Cytokinetics Announces Positive Topline Results From MAPLE-HCM

Cytokinetics Announces Positive Topline Results From MAPLE-HCM

Trial Demonstrates Superiority of Aficamten to Standard of Care Beta Blocker in Improving Peak Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, …

Prime Biome Reviews (Consumer Report 2025): The Gut Health and Skin Supplement That’s Getting Noticed

Prime Biome Reviews (Consumer Report 2025): The Gut Health and Skin Supplement That’s Getting Noticed

SAN JOSE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- I’ll be honest—I've tried more probiotics than I can count. From popular capsules at local stores to trendy gummies delivered from across the country, none of them lived up to the hype. Some offered short- …

AquaSculpt Reviews and Complaints: Is Aqua Sculpt’s Top Weight Loss Secrets Too Good to Believe? (Shocking Results!)

AquaSculpt Reviews and Complaints: Is Aqua Sculpt’s Top Weight Loss Secrets Too Good to Believe? (Shocking Results!)

AUSTIN, Texas, May 13, 2025 (GLOBE NEWSWIRE) -- AquaSculpt is among the most often discussed natural supplements for weight loss in 2025—and it's not hard to understand why. Search engines with searches like "Aqua Sculpt Pills," "Aqua Sculpt Weight Loss …

Plantsulin Reviews Consumer Reports 2025: Does It Really Work? The Truth Behind the Hype Exposed!

Plantsulin Reviews Consumer Reports 2025: Does It Really Work? The Truth Behind the Hype Exposed!

SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- In this Article, You’ll Learn: Why standard blood sugar advice doesn’t always work in real life — and what might actually make a difference How Plantsulin delivers plant-powered support for balanced glucose …

Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025

Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025

PRINCETON, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody- …

Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based upon CLOVER WaM Phase 2 Study Data CLOVER WaM Major Response Rate for BTKi-Treated Patients 59.0% Company to hold webcast …

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service